Sequential Capecitabine/Temozolomide and Sunitinib Treatment in Patients With Metastatic Well-Differentiated Grade 1/Grade 2 Pancreatic Neuroendocrine Tumors
- 25 August 2021
- journal article
- research article
- Published by Elsevier BV in Endocrine Practice
- Vol. 28 (3), 292-297
- https://doi.org/10.1016/j.eprac.2021.08.008
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy - Biotherapy and Novel Targeted AgentsNeuroendocrinology, 2017
- Sequential Everolimus and Sunitinib Treatment in Pancreatic Metastatic Well-Differentiated Neuroendocrine Tumours Resistant to Prior TreatmentsNeuroendocrinology, 2017
- Modified Staging Classification for Pancreatic Neuroendocrine Tumors on the Basis of the American Joint Committee on Cancer and European Neuroendocrine Tumor Society SystemsJournal of Clinical Oncology, 2017
- Analysis of potential response predictors to capecitabine/temozolomide in metastatic pancreatic neuroendocrine tumorsEndocrine-Related Cancer, 2016
- Efficiency of Sunitinib in Chinese Patients with Advanced Progressive Pancreatic Neuroendocrine Tumor.2016
- ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary SiteNeuroendocrinology, 2016
- Outcomes of patients treated with capecitabine and temozolamide for advanced pancreatic neuroendocrine tumors (PNETs) and non-PNETs2014
- Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine TumorsThe New England Journal of Medicine, 2011
- First‐line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomasCancer, 2010
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000